HireQuest Announces $20 Million Share Repurchase Program

HireQuest, Inc. (NASDAQ: HQI) ("HireQuest" or the "Company"), a global franchisor of on-demand staffing and executive search services, today announced that its Board of Directors has approved a share ...

Georgia Power and Atlanta Hawks expand HBCU Pathways program for fourth consecutive year

For the fourth consecutive year, Georgia Power will host the HBCU Pathways program in partnership with the Atlanta Hawks to support students from Historically Black Colleges and Universities (HBCUs) ...

AtkinsRéalis appointed to alliance delivering England's Midlands Rail Hub program

AtkinsRéalis Group Inc. (TSX: ATRL), a world-class engineering services and nuclear company with offices around the world, has been appointed by Network Rail, Britain's rail infrastructure owner, to ...

(CNW) Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

Market forecasters project the CAR-T cell therapy market will surge from $3.87 billion in 2024 to $13.25 billion by 2030, driven by unprecedented efficacy in relapsed and refractory patient ...

Bit by bit, small US groups chip away at historic levels of social isolation

Americans are disconnected from each other at historic levels, buffeted by what a former surgeon general calls an “epidemic ...

Boundless Devices Appoints David Henry as Chief Executive Officer

Industry veteran brings strong vision for home networking and a track record of customer-centric execution ...

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

Issued on behalf of GT Biopharma, Inc.VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- USA News Group News Commentary – The recent FDA approval in November of the first bispecific antibody combination for ...

BTQ Technologies Acquires Post-Quantum Cryptography IP Through Strategic Investment in Keypair, Accelerating Co-Development of Hardware-Rooted Security f…

BTQ Technologies Corp. ("BTQ" or the "Company") (Nasdaq: BTQ) (CBOE CA: BTQ) (FSE: NG3), a global quantum technology company ...
The Manila Times

Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to ...

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that the U.S. Food and ...

Galectin Therapeutics Inc.: Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard ...

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension ...

Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology

Norgine, a leading European specialty pharmaceutical company, today announced an exclusive licensing agreement under which ...

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease

Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5,with follow-up through 1 year at dose selected for Phase 2 Durable ...